Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Picture of an easyJet plane taking off.
Investing Articles

£10,000 invested in easyJet shares 2 days ago is now worth…

easyJet shares just experienced a sharp move higher. So anyone who invested in the budget airline operator two days ago…

Read more »

Wall Street sign in New York City
Investing Articles

I’m getting ready for a dramatic stock market crash

Our writer sees plenty of reasons that could mean a lot of stock market volatility is on the way. But…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£5,000 invested in BP shares 2 days ago is now worth…

BP shares were in a very strong upward trend. However, in the last few days they have pulled back amid…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 top FTSE 250 investment trusts to consider in April

The FTSE 250 is brimming with high-quality investment trusts. Our writer highlights two very different options, including a mid-cap newcomer.

Read more »

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
Investing Articles

After making a fortune on Tesla, this FTSE 250 trust has piled into a little-known S&P 500 stock

Baillie Gifford made huge profits from S&P 500 growth stocks like Nvidia. Lately, it's been snapping up a lesser-known tech…

Read more »

ISA coins
Investing Articles

How much do you need in a Stocks and Shares ISA to target a £1,200 a year passive income?

A FTSE 100 index fund comes with a 3% dividend yield. But can income investors find better opportunities for their…

Read more »

piggy bank, searching with binoculars
Value Shares

What’s going on with the Greggs share price now?

Dr James Fox takes a look at the Greggs share price which has suffered more than most over the past…

Read more »

Middle aged businesswoman using laptop while working from home
Dividend Shares

2 UK shares with over 20 years of consecutive dividend growth

Jon Smith points out a couple of UK shares with strong dividend credentials that lead him to dig deeper and…

Read more »